Synspira, a therapy whose developers say could revolutionize the battle against antibiotic-resistant lung infections in cystic fibrosis patients, eliminated resistant Staphylococcus aureus in a lab, a study reports.
The finding dealt with Synspira’s polycationic glycopolymer SNSP113 as a stand-alone treatment. The study also showed that the therapy increased the punch of antibiotics used to counter methicillin-resistant S. aureus, or MRSA.
Synspira’s partner, Synedgen, conducted the study, titled “In Vitroactivity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.” Synedgen develops glycopolymer-based treatments for infections and inflammatory disorders. Synspira obtained the rights to any inhaled treatments that Synedgen develops for lung diseases.